H.C. Wainwright raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $26 from $20 and keeps a Buy rating on the shares following the Q3 report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals Reports Strong Q3 2025 Growth
- Phathom Pharmaceuticals: Strong Q3 Performance and Promising Growth Drive Buy Rating
- Phathom Pharmaceuticals reports Q3 adjusted EPS (15c), consensus (41c)
- Phathom Pharmaceuticals sees cash sufficient to fund operations in 2026
- Phathom Pharmaceuticals sees FY25 revenue $170M-$175M, consensus $170.4M